Can the SARS-CoV-2 Omicron Variant Confer Natural Immunity against COVID-19?

被引:14
|
作者
Abas, Abdul Hawil [1 ]
Marfuah, Siti [1 ]
Idroes, Rinaldi [2 ]
Kusumawaty, Diah [3 ]
Fatimawali [4 ]
Park, Moon Nyeo [5 ]
Siyadatpanah, Abolghasem [6 ]
Alhumaydhi, Fahad A. [7 ]
Mahmud, Shafi [8 ]
Tallei, Trina Ekawati [1 ]
Bin Emran, Talha [9 ]
Kim, Bonglee [5 ]
机构
[1] Sam Ratulangi Univ, Fac Math & Nat Sci, Dept Biol, Manado 95115, North Sulawesi, Indonesia
[2] Univ Syiah Kuala, Fac Math & Nat Sci, Dept Pharm, Banda Aceh 23111, Aceh, Indonesia
[3] Univ Pendidikan Indonesia, Fac Math & Nat Sci Educ, Dept Biol, Bandung 40154, West Java, Indonesia
[4] Sam Ratulangi Univ, Fac Math & Nat Sci, Pharm Study Program, Manado 95115, North Sulawesi, Indonesia
[5] Kyung Hee Univ, Coll Korean Med, Seoul 05253, South Korea
[6] Birjand Univ Med Sci, Ferdows Sch Paramed & Hlth, Birjand 9717853577, Iran
[7] Qassim Univ, Coll Appl Med Sci, Dept Med Labs, Buraydah 52571, Saudi Arabia
[8] Australian Natl Univ, John Curtin Sch Med Res, Dept Genome Sci, Canberra, ACT 0200, Australia
[9] BGC Trust Univ Bangladesh, Dept Pharm, Chittagong 4381, Bangladesh
来源
MOLECULES | 2022年 / 27卷 / 07期
基金
新加坡国家研究基金会;
关键词
COVID-19; SARS-CoV-2; Omicron; natural immunity; hybrid immunity; MAIN PROTEASE; TRANSMISSION; MECHANISMS; INFECTION; VACCINES; FUTURE; ORIGIN;
D O I
10.3390/molecules27072221
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The coronavirus disease 2019 (COVID-19) pandemic is still ongoing, with no signs of abatement in sight. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the causative agent of this pandemic and has claimed over 5 million lives, is still mutating, resulting in numerous variants. One of the newest variants is Omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated. As a result, many believe that Omicron provides a natural vaccination, which is the first step toward ending the COVID-19 pandemic. Based on published research and scientific evidence, we review and discuss how the end of this pandemic is predicted to occur as a result of Omicron variants being surpassed in the community. In light of the findings of our research, we believe that it is most likely true that the Omicron variant is a natural way of vaccinating the masses and slowing the spread of this deadly pandemic. While the mutation that causes the Omicron variant is encouraging, subsequent mutations do not guarantee that the disease it causes will be less severe. As the virus continues to evolve, humans must constantly adapt by increasing their immunity through vaccination.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review
    Chen, Zhonghao
    Zhang, Ying
    Wang, Meng
    Islam, Md Sahidul
    Liao, Ping
    Hu, Yuanjia
    Chen, Xin
    INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2022, 18 (11): : 4629 - 4641
  • [22] Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant
    Ioannis Sitaras
    Henning Jacobsen
    Melissa M. Higdon
    William E. Dowling
    Naor Bar-Zeev
    Maria Deloria Knoll
    npj Vaccines, 7
  • [23] Reduced neutralizing antibody potency of COVID-19 convalescent vaccinated plasma against SARS-CoV-2 Omicron variant
    Gallian, Pierre
    Amroun, Abdennour
    Laperche, Syria
    Le Cam, Sophie
    Brisbarre, Nadege
    Malard, Lucile
    Nurtop, Elif
    Isnard, Christine
    Richard, Pascale
    Morel, Pascal
    Tiberghien, Pierre
    de Lamballerie, Xavier
    VOX SANGUINIS, 2022, 117 (07) : 971 - 975
  • [24] Breakthrough infection shapes humoral immunity against SARS-CoV-2 Omicron Variant
    Zhang, Yuwei
    Han, Shanshan
    Guo, Xingyu
    Yao, Mingxiao
    Zhao, Lianxiang
    Sun, Wenkui
    Wang, Shuang
    Pang, Bo
    Zhang, Shu
    Wang, Jianxing
    Fang, Ming
    Liu, Xiaolin
    Kou, Zengqiang
    Jiang, Xiaolin
    JOURNAL OF INFECTION, 2023, 86 (02) : E40 - E42
  • [25] Systematic review of primary and booster COVID-19 sera neutralizing ability against SARS-CoV-2 omicron variant
    Sitaras, Ioannis
    Jacobsen, Henning
    Higdon, Melissa M.
    Dowling, William E.
    Bar-Zeev, Naor
    Knoll, Maria Deloria
    NPJ VACCINES, 2022, 7 (01)
  • [26] Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study
    Gram, Mie Agermose
    Emborg, Hanne-Dorthe
    Schelde, Astrid Blicher
    Friis, Nikolaj Ulrik
    Nielsen, Katrine Finderup
    Moustsen-Helms, Ida Rask
    Legarth, Rebecca
    Lam, Janni Uyen Hoa
    Chaine, Manon
    Malik, Aisha Zahoor
    Rasmussen, Morten
    Fonager, Jannik
    Sieber, Raphael Niklaus
    Stegger, Marc
    Ethelberg, Steen
    Valentiner-Branth, Palle
    Hansen, Christian Holm
    PLOS MEDICINE, 2022, 19 (09)
  • [27] Cross-reactive immunity against the SARS-CoV-2 Omicron variant is low in pediatric patients with prior COVID-19 or MIS-C
    Juanjie Tang
    Tanya Novak
    Julian Hecker
    Gabrielle Grubbs
    Fatema Tuz Zahra
    Lorenza Bellusci
    Sara Pourhashemi
    Janet Chou
    Kristin Moffitt
    Natasha B. Halasa
    Stephanie P. Schwartz
    Tracie C. Walker
    Keiko M. Tarquinio
    Matt S. Zinter
    Mary A. Staat
    Shira J. Gertz
    Natalie Z. Cvijanovich
    Jennifer E. Schuster
    Laura L. Loftis
    Bria M. Coates
    Elizabeth H. Mack
    Katherine Irby
    Julie C. Fitzgerald
    Courtney M. Rowan
    Michele Kong
    Heidi R. Flori
    Aline B. Maddux
    Steven L. Shein
    Hillary Crandall
    Janet R. Hume
    Charlotte V. Hobbs
    Adriana H. Tremoulet
    Chisato Shimizu
    Jane C. Burns
    Sabrina R. Chen
    Hye Kyung Moon
    Christoph Lange
    Adrienne G. Randolph
    Surender Khurana
    Nature Communications, 13
  • [28] COVID-19 vaccination and SARS-CoV-2 Omicron (B.1.1.529) variant: a at the end of the tunnel?
    Mattiuzzi, Camilla
    Henry, Brandon M.
    Lippi, Giuseppe
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 118 : 167 - 168
  • [29] Structure genomics of SARS-CoV-2 and its Omicron variant: drug design templates for COVID-19
    Can-rong Wu
    Wan-chao Yin
    Yi Jiang
    H. Eric Xu
    Acta Pharmacologica Sinica, 2022, 43 : 3021 - 3033
  • [30] COVID-19: Omicron - the latest, the least virulent, but probably not the last variant of concern of SARS-CoV-2
    Bruessow, Harald
    MICROBIAL BIOTECHNOLOGY, 2022, 15 (07): : 1927 - 1939